Pharvaris B.V. (PHVS) Stock Forecast & Price Target

Pharvaris NV has raised its global peak sales estimate for deucrictibant to $1.65 billion by 2037, reflecting increased confidence in its market potential. Positive clinical trial results highlight that all participants demonstrated "well-controlled HAE" status and significant improvements in health-related quality of life after treatment. With the estimated prevalence of HAE ranging from 1:100,000 to 1:500,000 and a notable lack of approved therapies, deucrictibant is positioned to capture significant market share if it receives regulatory approval.

Pharvaris NV faces significant challenges in the competitive Hereditary Angioedema (HAE) market, which is already dominated by established therapies and segment leaders, potentially limiting the uptake of its novel treatment, deucrictibant. The company also encounters concerns regarding the de-risking of bradykinin B2 receptor antagonism in the chronic prophylaxis setting, raising questions about the efficacy and desirability of its product. Furthermore, the anticipated approval of multiple subcutaneous therapies over the next 36 months could further erode Pharvaris's market share, adversely affecting its financial outlook and long-term viability.